Welcome to our dedicated page for CytomX Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytomX Therapeutics filings document a Delaware clinical-stage oncology biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under CTMX. Recent 8-K reports furnish quarterly and annual financial results, business updates, clinical-program disclosures for Varseta-M and other PROBODY programs, and clinical safety reporting tied to the company’s development studies.
Its formal records also cover capital structure and financing activity, including a completed public offering of common stock and pre-funded warrants made through a Form S-3 registration framework. Proxy materials describe board elections, auditor ratification, authorized-share amendments, equity incentive plan matters, executive compensation, and stockholder voting procedures.
BlackRock, Inc. reports a significant ownership position in CytomX Therapeutics, Inc. common stock on a passive Schedule 13G basis. BlackRock beneficially owns 16,551,452 shares, representing 7.6% of the outstanding common stock. It has sole voting power over 16,307,550 shares and sole dispositive power over all 16,551,452 shares, with no shared voting or dispositive power. Various underlying clients and accounts have rights to dividends or sale proceeds from these shares, but no single such person holds more than five percent of CytomX’s total outstanding common stock. The filing is signed on behalf of BlackRock by a managing director.
CytomX Therapeutics, Inc. appointed Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective July 24, 2026, with an initial term running until the company’s 2029 annual meeting of stockholders. He will receive the company’s standard non-employee director compensation.
Upon joining the board, Dr. Fuchs was granted an option to purchase 118,000 shares of common stock under the 2015 Equity Incentive Plan, with an exercise price equal to the closing price on July 24, 2026. The option vests as to 1/36th of the shares each month, subject to his continued service. The company will also enter into its standard indemnification agreement with him and states there are no related-party transactions over $120,000 or special arrangements connected to his appointment.
CytomX Therapeutics director Su Zhen received a grant of stock options covering 59,000 shares of common stock. The options were awarded at an exercise price of $2.96 per share and are held directly. Following this grant, Su Zhen holds stock options for 59,000 shares.
According to the vesting terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that vesting date.
CytomX Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved several governance and equity-related proposals. The company later filed a charter amendment to reflect these changes.
Stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 6,500,000 shares, and an amendment to the Amended and Restated Employee Stock Purchase Plan to increase shares authorized thereunder by 1,000,000 shares. Both amendments were previously adopted by the board and became effective upon stockholder approval.
Stockholders also approved a charter amendment increasing the authorized number of shares of common stock from 300,000,000 to 600,000,000 shares. All management proposals, including the election of two Class II directors, ratification of Ernst & Young LLP as auditor, executive compensation on an advisory basis, and holding future say-on-pay votes every year, received sufficient support, with broker non-votes recorded where applicable.
CytomX Therapeutics director Matthew P. Young received a grant of stock options representing rights to buy 59,000 shares of common stock at an exercise price of $2.96 per share.
All 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of CytomX stockholders, as long as he continues serving as a director until that vesting date.
CytomX Therapeutics director Mani Mohindru received a grant of 59,000 stock options for Common Stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036. All 59,000 options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continuous service as a director.
CytomX Therapeutics, Inc. director James R. Meyers received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the award terms, 100% of the options will vest on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds 59,000 derivative securities directly, reflecting a compensation-related award rather than an open‑market purchase.
CytomX Therapeutics director Halley E. Gilbert received a new stock option grant for 59,000 shares of common stock at an exercise price of $2.96 per share. This is a compensation-related award, not an open-market purchase or sale.
The option vests in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that date. Following this grant, Gilbert is reported as holding 59,000 stock options directly.
CytomX Therapeutics director Alan Ashworth received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or the 2027 annual meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds options for 59,000 shares directly.
CytomX Therapeutics, Inc. reported that director Elaine V. Jones received a stock option grant. She was awarded options to acquire 59,000 shares of common stock at an exercise price of $2.96 per share, giving her rights to buy shares at that price in the future.
After this grant, she holds 59,000 derivative securities linked to common stock. According to the terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 annual stockholder meeting, assuming she continues serving as a director until that vesting date.